Preclinical modeling of EGFR inhibitor resistance in head and neck cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71 - 96; http://dx.doi.org/10.3322/CA.2007.0010; PMID: 18287387
   PubMed Web of Science ®Google Scholar
• Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5:127 - 35; http://dx.doi.org/10.1038/nrc1549; PMID: 15685196
   PubMed Web of Science ®Google Scholar
• Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83:489 - 501; http://dx.doi.org/10.4065/83.4.489; PMID: 18380996
   PubMed Web of Science ®Google Scholar
• Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005; 52:338 - 43; PMID: 16059652
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579 - 84; PMID: 8339264
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116 - 27; http://dx.doi.org/10.1056/NEJMoa0802656; PMID: 18784101
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77 - 85; http://dx.doi.org/10.1200/JCO.2004.06.075; PMID: 14701768
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171 - 7; http://dx.doi.org/10.1200/JCO.2006.06.7447; PMID: 17538161
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090 - 101; PMID: 11431346
   PubMed Web of Science ®Google Scholar
• Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010; 16:2095 - 105; http://dx.doi.org/10.1158/1078-0432.CCR-09-2495; PMID: 20215534
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337 - 45; http://dx.doi.org/10.1056/NEJMoa033025; PMID: 15269313
   PubMed Web of Science ®Google Scholar
• Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011; 17:5935 - 44; http://dx.doi.org/10.1158/1078-0432.CCR-11-0370; PMID: 21791633
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10:784 - 93; http://dx.doi.org/10.1158/1078-0432.CCR-1100-03; PMID: 14760102
   PubMed Web of Science ®Google Scholar
• Paranavitana CM. Non-radioactive detection of K-ras mutations by nested allele specific PCR and oligonucleotide hybridization. Mol Cell Probes 1998; 12:309 - 15; http://dx.doi.org/10.1006/mcpr.1998.0185; PMID: 9778456
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69:3021 - 31; http://dx.doi.org/10.1158/0008-5472.CAN-08-2881; PMID: 19318576
   PubMed Web of Science ®Google Scholar
• Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15:1585 - 92; http://dx.doi.org/10.1158/1078-0432.CCR-08-2068; PMID: 19190133
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947 - 57; http://dx.doi.org/10.1056/NEJMoa0810699; PMID: 19692680
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 2007; 6:2168 - 77; http://dx.doi.org/10.1158/1535-7163.MCT-06-0514; PMID: 17671085
   PubMed Web of Science ®Google Scholar
• Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010; 107:15535 - 40; http://dx.doi.org/10.1073/pnas.1009472107; PMID: 20713723
   PubMed Web of Science ®Google Scholar
• Muller S, Su L, Tighiouart M, Saba N, Zhang H, Shin DM, et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. Cancer 2008; 113:97 - 107; http://dx.doi.org/10.1002/cncr.23557; PMID: 18473353
   PubMed Web of Science ®Google Scholar
• Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 2009; 15:532 - 42; http://dx.doi.org/10.1158/1078-0432.CCR-08-1733; PMID: 19147758
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al, Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23:6838 - 45; http://dx.doi.org/10.1200/JCO.2005.01.2823; PMID: 15998906
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643 - 55; http://dx.doi.org/10.1093/jnci/dji112; PMID: 15870435
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25:2248 - 55; http://dx.doi.org/10.1200/JCO.2006.09.4300; PMID: 17538169
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587 - 95; http://dx.doi.org/10.1200/JCO.2006.07.3585; PMID: 17290067
   PubMed Web of Science ®Google Scholar
• Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25:2184 - 90; http://dx.doi.org/10.1200/JCO.2006.07.6554; PMID: 17538163
   PubMed Web of Science ®Google Scholar
• Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007; 29:163 - 88; http://dx.doi.org/10.1002/hed.20478; PMID: 17312569
   PubMed Web of Science ®Google Scholar
• Wheeler DLHS, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944 - 56; http://dx.doi.org/10.1038/onc.2008.19; PMID: 18297114
   PubMed Web of Science ®Google Scholar
• Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13:4909 - 19; http://dx.doi.org/10.1158/1078-0432.CCR-07-0701; PMID: 17699871
   PubMed Web of Science ®Google Scholar
• Studer G, Lütolf UM, El-Bassiouni M, Rousson V, Glanzmann C. Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol 2007; 46:386 - 94; http://dx.doi.org/10.1080/02841860600815407; PMID: 17450476
   PubMed Web of Science ®Google Scholar
• Garber K. From human to mouse and back: ‘tumorgraft’ models surge in popularity. J Natl Cancer Inst 2009; 101:6 - 8; http://dx.doi.org/10.1093/jnci/djn481; PMID: 19116380
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 10:1311 - 6; http://dx.doi.org/10.1158/1535-7163.MCT-11-0233; PMID: 21673092
   PubMed Web of Science ®Google Scholar
• Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP, et al. Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. J Clin Oncol 2011; PMID: 22184402
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12:2166 - 71; http://dx.doi.org/10.1158/1078-0432.CCR-05-2235; PMID: 16609030
   PubMed Web of Science ®Google Scholar
• Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009; 69:873 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-08-3118; PMID: 19155297
   PubMed Web of Science ®Google Scholar
• Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004; 10:7547 - 54; http://dx.doi.org/10.1158/1078-0432.CCR-04-1169; PMID: 15569985
   PubMed Web of Science ®Google Scholar
• Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011; 17:7248 - 64; http://dx.doi.org/10.1158/1078-0432.CCR-11-0690; PMID: 21868764
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33 - 42; http://dx.doi.org/10.1016/S1470-2045(11)70318-7; PMID: 22056021
   PubMed Web of Science ®Google Scholar
• López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009; 58:1853 - 64; http://dx.doi.org/10.1007/s00262-009-0697-4; PMID: 19319529
   PubMed Web of Science ®Google Scholar
• Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem 2011; 286:20558 - 68; http://dx.doi.org/10.1074/jbc.M111.240796; PMID: 21487020
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28:3801 - 13; http://dx.doi.org/10.1038/onc.2009.234; PMID: 19684613
   PubMed Web of Science ®Google Scholar
• Thomas JM. A lung colony clonogenic cell assay for human malignant melanoma in immune-suppressed mice and its use to determine chemosensitivity, radiosensitivity and the relationship between tumour size and response to therapy. Br J Surg 1979; 66:696 - 700; http://dx.doi.org/10.1002/bjs.1800661007; PMID: 509043
   PubMed Web of Science ®Google Scholar
• Zhu S, Belkhiri A, El-Rifai W. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology 2011; 141:1738-48 e1-2.
   Google Scholar
• Bubeník J, Baresová M, Viklický V, Jakoubková J, Sainerová H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973; 11:765 - 73; http://dx.doi.org/10.1002/ijc.2910110327; PMID: 4133950
   PubMed Web of Science ®Google Scholar
• Linsley PS, Fox CF. Direct linkage of EGF to its receptor: characterization and biological relevance. J Supramol Struct 1980; 14:441 - 59; http://dx.doi.org/10.1002/jss.400140404; PMID: 6264232
   PubMedGoogle Scholar
• Scherer WF, Syverton JT, Gey GO. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 1953; 97:695 - 710; http://dx.doi.org/10.1084/jem.97.5.695; PMID: 13052828
   PubMed Web of Science ®Google Scholar